<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-5633</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Colomb. Cardiol.]]></abbrev-journal-title>
<issn>0120-5633</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Cardiologia. Oficina de Publicaciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-56332016000500351</article-id>
<article-id pub-id-type="doi">10.1016/j.rccar.2015.10.009</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Relevancia clínica de la interacción de la warfarina y del acetaminofén: estudio de cohortes retrospective]]></article-title>
<article-title xml:lang="en"><![CDATA[Clinical relevance of the interaction of warfarin and acetaminophen: retrospective cohort study]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ceballos]]></surname>
<given-names><![CDATA[Mauricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[César A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Holguín]]></surname>
<given-names><![CDATA[Héctor A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Amariles]]></surname>
<given-names><![CDATA[Pedro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Antioquia UdeA Facultad de Ciencias Farmacéuticas y Alimentarias ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Antioquia Facultad de Ciencias Farmacéuticas y Alimentarias ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Antioquia Facultad de Ciencias Farmacéuticas y Alimentarias ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2016</year>
</pub-date>
<volume>23</volume>
<numero>5</numero>
<fpage>351</fpage>
<lpage>360</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-56332016000500351&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-56332016000500351&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-56332016000500351&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  Evaluar el uso concomitante de la warfarina y el acetaminofén en una población ambulatoria de pacientes anticoagulados, como posible factor de riesgo en el aumento de la Relación Normalizada Internacional (INR).  Métodos:  Estudio de cohortes retrospectivo. Se analizó la información de 1.458 pacientes anticoagulados con la warfarina. El factor de riesgo fue la utilización conjunta de warfarina- acetaminofén; el tiempo de seguimiento fue de 1 mes y como evento final se consideró un incremento del INR igual o mayor a 0,5 unidades. La asociación del factor de riesgo con el evento final se estableció con el riesgo relativo (RR) y el riesgo atribuible poblacional (RAP). Resultados: 63 pacientes cumplieron criterios de inclusión, 21 pacientes expuestos y 42 pacientes no expuestos. En los individuos expuestos se observó un aumento estadísticamente significativo en el INR al mes siguiente de haber iniciado el tratamiento con el acetaminofén comparado con el momento de ingreso al estudio (mes 1: mediana 3,06 vs. mes 0: mediana 2,63), (valor p = 0,003). En contraste, en los sujetos no expuestos no se observaron diferencias estadísticamente significativas en los valores del INR (mes 0: mediana 2,63 vs. mes 1: mediana 2,75), (valor p = 0,115). El uso de la warfarina y el acetaminofén representó un RR de 2,5 veces mayor de incrementar el INR mayor o igual de 0,5 unidades.  Conclusión:  El uso concomitante de la warfarina y el acetaminofén está asociado a un aumento del INR igual o mayor de 0,5 unidades, lo cual podría generar un mayor efecto anticoagulante y, por tanto, un mayor riesgo potencial de sangrado.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Motivation:  To assess concomitant use of warfarin and acetaminophen in an outpatient population of patients receiving blood-thinning drugs as a possible risk factor for the increase of International Normalised Ratio (INR).  Methods:  Retrospective cohort study. The information pertaining 1,458 patients receiving blood-thinning drugs with warfarin was analysed. The risk factor was the joint intake of warfarin and acetaminophen; follow-up time was 1 month and the final event considered was a INR increase of or higher than 0.5 units. The association of the risk factor with the final event was establish with the Relative Risk (RR) and the Population Attributable Risk (PAR).  Results:  63 patients met the inclusion criteria, of whom 21 were exposed patients and 42 were unexposed patients. In the exposed patients a statistically significant increase of INR on the month following the onset of treatment with acetaminophen was observed, compared to the baseline values (month 1: median 3.06 vs. month 0: median 2.63), (p = 0.003). In contrast, no statistically significant differences of INR values were observed in unexposed individuals (month 0: median 2.63 vs. month 1: median 2.75) (p = 0.115). The combination of warfarin and acetaminophen represented a RR 2.5 times higher to increase INR greater than or equal to 0.5 units.  Conclusion:  Concomitant use of warfarin and acetaminophen is associated to an increase of INR equal to or greater than 0.5 units, which could generate a higher blood-thinning effect and, thus, cause a potentially higher risk of bleeding.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Tratamiento anticoagulante]]></kwd>
<kwd lng="es"><![CDATA[Factores de riesgo]]></kwd>
<kwd lng="es"><![CDATA[Hemorragia]]></kwd>
<kwd lng="en"><![CDATA[Blood-thinning treatment]]></kwd>
<kwd lng="en"><![CDATA[Risk factors]]></kwd>
<kwd lng="en"><![CDATA[Haemorrage]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meckley]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Gudgeon]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Veenstra]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacoecono- mics]]></source>
<year>2010</year>
<volume>28</volume>
<page-range>61-74</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The risk for and severity of bleeding complications in elderly patients treated with warfarin The National Consortium of Anticoagulation Clinics.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fihn]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Callahan]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[McDonell]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Henikoff]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Intern Med]]></source>
<year>1996</year>
<volume>124</volume>
<page-range>970-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Acetaminophen and other risk factors for excessive warfarin anticoagulation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hylek]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Heiman]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Skates]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sheehan]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<source><![CDATA[JAMA]]></source>
<year>1998</year>
<volume>279</volume>
<page-range>657-62</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Warfarin dosing and cytochrome P450 2C9 polymorphisms Thromb]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joffe]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[Longtine]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kucher]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Goldhaber]]></surname>
<given-names><![CDATA[SZ]]></given-names>
</name>
</person-group>
<source><![CDATA[Haemost]]></source>
<year>2004</year>
<volume>91</volume>
<page-range>1123-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hirsh]]></surname>
<given-names><![CDATA[J,]]></given-names>
</name>
<name>
<surname><![CDATA[Dalen]]></surname>
<given-names><![CDATA[J,]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[DR,]]></given-names>
</name>
<name>
<surname><![CDATA[Poller]]></surname>
<given-names><![CDATA[L,]]></given-names>
</name>
<name>
<surname><![CDATA[Bussey]]></surname>
<given-names><![CDATA[H,]]></given-names>
</name>
<name>
<surname><![CDATA[Ansell]]></surname>
<given-names><![CDATA[J,]]></given-names>
</name>
</person-group>
<source><![CDATA[Chest.]]></source>
<year>2001</year>
<volume>119</volume>
<page-range>8S-21S</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Co-Prescribing of Potentially Interacting Drugs during Warfarin Therapy - A Population-Based Register Study.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rikala]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hauta-Aho]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Helin-Salmivaara]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lassila]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Korho- nen]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Huupponen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Basic Clin Pharmacol Toxicol]]></source>
<year>2014</year>
<volume>117</volume>
<page-range>126-32</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="">
<article-title xml:lang=""><![CDATA[Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
</person-group>
<source><![CDATA[Cardiol. Clin.]]></source>
<year>2008</year>
<volume>26</volume>
<page-range>157-67</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="">
<article-title xml:lang=""><![CDATA[The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosand]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Eckman]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Knudsen]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Greenberg]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch. Intern. Med.]]></source>
<year>2004</year>
<volume>164</volume>
<page-range>80-4</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Modifiable risk factors for intracerebral hemorrhage: study of anticoagulated patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fric-Shamji]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Shamji]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Cole]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Benoit]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
</person-group>
<source><![CDATA[Can. Fam. Physician]]></source>
<year>2008</year>
<volume>54</volume>
<page-range>1138-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Kase]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
<name>
<surname><![CDATA[Hoeben]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<source><![CDATA[Mayo Clin. Proc]]></source>
<year>2007</year>
<numero>82</numero>
<issue>82</issue>
<page-range>82-92</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Wafarina uso contemporaneo. Rev]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Francisco]]></surname>
<given-names><![CDATA[JYR]]></given-names>
</name>
</person-group>
<source><![CDATA[Med]]></source>
<year>2009</year>
<volume>17</volume>
<page-range>107-15</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Interaction between paracetamol and warfarin in patients a double-blind, placebo-controlled, randomized study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahé]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bertrand]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Drouet]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bal Dit-Sollier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Simoneau]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mazoyer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Haematológica]]></source>
<year>2006</year>
<volume>91</volume>
<page-range>1621-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahé]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bertrand]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Drouet]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Simoneau]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mazoyer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Paracetamol a haemorrhagic risk factor in patients on warfarin]]></article-title>
<collab>Bal Dit Sollier C</collab>
<source><![CDATA[Br. J. Clin. Pharmacol.]]></source>
<year>2005</year>
<volume>59</volume>
<page-range>371-4</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kwan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bartle]]></surname>
<given-names><![CDATA[WR]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<source><![CDATA[J. Clin. Pharmacol.]]></source>
<year>1999</year>
<volume>39</volume>
<page-range>68-75</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effect of acetaminophen on the international normalized ratio in patients stabilized on warfarin therapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parra]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Beckey]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacotherapy]]></source>
<year>2007</year>
<volume>27</volume>
<page-range>675-83</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Clinical practice Care of patients receiving longterm anticoagulant therapy.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schulman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[N. Engl. J. Med.]]></source>
<year>2003</year>
<volume>349</volume>
<page-range>675-83</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Paracetamol (acetaminophen) warfarin interaction NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thijssen]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Soute]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Vervoort]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Claessens]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<source><![CDATA[Thromb. Haemost]]></source>
<year>2004</year>
<volume>92</volume>
<page-range>797-802</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Interpretation of serial measurements of international normalized ratio for prothrombin times in monitoring oral anti coagulant therapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lassen]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Kjeldsen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Antonsen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hyltoft Petersen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Brands- lund]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin. Chem.]]></source>
<year>1995</year>
<volume>41</volume>
<page-range>1171-6</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Warfarin and acetaminophen interaction Assessment to establish its clinical relevance]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ceballos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Holguín]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Amariles]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Acta Medica Colomb.]]></source>
<year>2013</year>
<volume>38</volume>
<page-range>22-5</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Clinical relevance of drug inte- ractions.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amariles]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Giraldo]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Faus]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Med. Clin. (Barc)]]></source>
<year>2007</year>
<volume>129</volume>
<page-range>27-35</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Acetaminophen causes an increased International Normalized Ratio by reducing functional factor VII]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whyte]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Buckley]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Reith]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Goodhew]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Seldon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dawson]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
</person-group>
<source><![CDATA[Ther. Drug Monit.]]></source>
<year>2000</year>
<volume>22</volume>
<page-range>742-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Son]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[J. Korean Med. Sci]]></source>
<year>2010</year>
<volume>25</volume>
<page-range>337-41</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Frequency of bleeding in patients with cardiovascular disease on anticoagulant therapy with generic warfarin vs Coumadin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Builes]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Arango]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cano]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
</person-group>
<source><![CDATA[Acta Medica Colomb.]]></source>
<year>2010</year>
<volume>35</volume>
<page-range>175-8</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy and tolerability of the switch from a branded to a generic warfarin sodium product an observer-blinded, randomized, crossover study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Kan]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin. Ther]]></source>
<year>2005</year>
<volume>27</volume>
<page-range>309-19</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Observational cohort study of switching warfarin sodium products in a managed care organization]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Swenson]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Fundak]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Am. J. Health. Syst. Pharm.]]></source>
<year>2000</year>
<volume>57</volume>
<page-range>452-5</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Subs- titution of generic warfarin for Coumadin in an HMO setting]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Milligan]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Banet]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Waterman]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Gatchel]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Gage]]></surname>
<given-names><![CDATA[BF]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann. Pharmacother.]]></source>
<year>2002</year>
<volume>36</volume>
<page-range>764-8</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="">
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="">
<article-title xml:lang=""><![CDATA[Utilization review of concomitant use of potentially interacting drugs in Thai patients using warfarin therapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kotirum]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chaiyakunapruk]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Jampachaisri]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Wattanasombat]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rojnuckarin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacoepidemiol. Drug Saf]]></source>
<year>2007</year>
<volume>16</volume>
<page-range>216-22</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Paracetamol (Acetaminophen) mechanisms of action.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Paediatr. Anaesth.]]></source>
<year>2008</year>
<volume>18</volume>
<page-range>915-21</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine a longitudinal analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shalansky]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lynd]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Richardson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ingaszewski]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kerr]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacotherapy]]></source>
<year>2007</year>
<volume>27</volume>
<page-range>1237-47</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="">
<article-title xml:lang=""><![CDATA[Potentiation of oral anticoa gulant therapy by acetaminophen.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Antlitz]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Mead]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Tolentino]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr. Ther. Res. Clin. Exp.]]></source>
<year>1968</year>
<volume>10</volume>
<page-range>501-7</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Implementation of a pharmacist-driven pain management consultation service for hospitalised adults with a history of substance abuse.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andrews]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Bridgeman]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Dalal]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Abazia]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Goldsmith]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
</person-group>
<source><![CDATA[Int. J. Clin. Pract.]]></source>
<year>2013</year>
<volume>67</volume>
<page-range>1342-9</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Warfarin and acetaminophen interaction]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gebauer]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Nyfort-Hansen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Henschke]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gallus]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacotherapy]]></source>
<year>2003</year>
<volume>23</volume>
<page-range>109-12</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Risk factors for intracranial hemorrhage in outpatients taking warfarin.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hylek]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann. Intern. Med.]]></source>
<year>1994</year>
<volume>120</volume>
<page-range>897-902</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
